CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc.

1:24-cv-00940

Overview

Case Number 1:24-cv-00940
Filing Date 2024-08-13
Status Litigation filed
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

Zydus Lifesciences Limited NPE (University / Research)

Represented By

7 Attorneys Listed

Michael J. Gaertner

Email: michael.gaertner@bipc.com

Leah M. Brackensick

Email: leah.brackensick@bipc.com

Jonathan B. Turpin

Email: jonathan.turpin@bipc.com

Emily L. Savas

Email: emily.savas@bipc.com

David B. Abramowitz

Email: david.abramowitz@bipc.com

Carolyn A. Blessing

Email: carolyn.blessing@bipc.com

Alexis Stombaugh

Young Conaway Stargatt & Taylor

Tel: +1 (302) 571-6600

Young Conaway Stargatt & Taylor, 1000 North King Street

Zydus Pharmaceuticals (USA) Inc. Operating Company

Represented By

7 Attorneys Listed

Michael J. Gaertner

Email: michael.gaertner@bipc.com

Leah M. Brackensick

Email: leah.brackensick@bipc.com

Jonathan B. Turpin

Email: jonathan.turpin@bipc.com

Emily L. Savas

Email: emily.savas@bipc.com

David B. Abramowitz

Email: david.abramowitz@bipc.com

Carolyn A. Blessing

Email: carolyn.blessing@bipc.com

Alexis Stombaugh

Young Conaway Stargatt & Taylor

Tel: +1 (302) 571-6600

Young Conaway Stargatt & Taylor, 1000 North King Street

Plaintiff

Astellas Pharma Global Development, Inc. Operating Company

Represented By

5 Attorneys Listed

Michael DelRossi

Email: michael.delrossi@kirkland.com

James F. Hurst

Email: james.hurst@kirkland.com

Diva Hollis

Email: diva.hollis@kirkland.com

Alexandra M. Joyce

McCarter & English, LLP

Tel: +1 (302) 984-6392
Fax: +1 (302) 450-4235

Renaissance Centre, 405 N. King Street, 8th Floor

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Astellas Ireland Co., Ltd. Operating Company

Represented By

5 Attorneys Listed

Michael DelRossi

Email: michael.delrossi@kirkland.com

James F. Hurst

Email: james.hurst@kirkland.com

Diva Hollis

Email: diva.hollis@kirkland.com

Alexandra M. Joyce

McCarter & English, LLP

Tel: +1 (302) 984-6392
Fax: +1 (302) 450-4235

Renaissance Centre, 405 N. King Street, 8th Floor

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Astellas Pharma Inc. Operating Company

Represented By

5 Attorneys Listed

Michael DelRossi

Email: michael.delrossi@kirkland.com

James F. Hurst

Email: james.hurst@kirkland.com

Diva Hollis

Email: diva.hollis@kirkland.com

Alexandra M. Joyce

McCarter & English, LLP

Tel: +1 (302) 984-6392
Fax: +1 (302) 450-4235

Renaissance Centre, 405 N. King Street, 8th Floor

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 6 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 1 proceeding
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (6): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (1 found):
U.S. Courts: 1
U.S. District Court 2024-08-13
1:24-cv-00939

Astellas Pharma Inc. v. Lupin Ltd.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US12059409
Pharmaceutical composition for modified release
Filed: 2024-03-22
Issued: 2024-08-13
Active (17.3 yrs remaining)
Expires: 2044-03-22

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked.

Docket Entries

(20 total)
Pleading / Complaint

COMPLAINT for PATENT INFRINGEMENT filed with Jury Demand against Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc. ( Filing fee $ 405, receipt number ADEDC-4475049.) - filed by Astellas Pharma Inc., Astellas Pharma Global Development, Inc., Astellas Ireland Co., Ltd.. (Attachments: # 1 Exhibit A-I, # 2 Civil Cover Sheet)(oam) (Entered: 08/14/2024)

Entry #1 • 2024-08-13
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (Entered: 08/14/2024)

Entry #2 • 2024-08-13
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 12,059,409. (oam) (Entered: 08/14/2024)

Entry #3 • 2024-08-13
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Astellas B.V. for Astellas Ireland Co., Ltd.; Corporate Parent Astellas US Holding, Inc. for Astellas Pharma Global Development, Inc. filed by Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.. (oam) (Entered: 08/14/2024)

Entry #4 • 2024-08-13
1

Summons Issued as to Zydus Lifesciences Limited on 8/13/2024; Zydus Pharmaceuticals (USA) Inc. on 8/13/2024. (Attachments: # 1 Summons Issued)(oam) (Entered: 08/14/2024)

Entry #5 • 2024-08-13
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc